Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA Panel
Citations Over TimeTop 1% of 2003 papers
Abstract
New information about the benefits and limitations of testing for resistance to human immunodeficiency virus (HIV) type 1 (HIV-1) drugs has emerged. The International AIDS Society-USA convened a panel of physicians and scientists with expertise in antiretroviral drug management, HIV-1 drug resistance, and patient care to provide updated recommendations for HIV-1 resistance testing. Published data and presentations at scientific conferences, as well as strength of the evidence, were considered. Properly used resistance testing can improve virological outcome among HIV-infected individuals. Resistance testing is recommended in cases of acute or recent HIV infection, for certain patients who have been infected as long as 2 years or more prior to initiating therapy, in cases of antiretroviral failure, and during pregnancy. Limitations of resistance testing remain, and more study is needed to refine optimal use and interpretation.
Related Papers
- → Current Perspectives on HIV-1 Antiretroviral Drug Resistance(2014)160 cited
- → Occurrence of transmitted HIV-1 drug resistance among Drug-naïve pregnant women in selected HIV-care centres in Ghana(2017)13 cited
- → Presence of HIV drug resistance in antiretroviral therapy-naive and -experienced patients from Papua New Guinea(2014)11 cited
- [A problem of the HIV drug resistance].(2015)
- → A Case of a Highly Drug-Resistant HIV Detected after Irregular Use of a Self-Prescribed Antiretroviral Drug(2022)